Engineered bioactive peptides derived from maize alpha-zein for multiple applications

Overview

This solution offers a portfolio of novel bioactive peptides derived from alpha-zein, the main constitutive protein of maize. The lead candidate, NurP28, along with three additional characterized peptides (19ZP1, 19ZP2, and 19ZP3), were identified from the 19 kDa and 22 kDa alpha-zein protein sequences. These engineered peptides are designed to serve multiple goals across potential applications in food, nutraceuticals, cosmetics, and biomedical sectors. By leveraging naturally occurring plant proteins as a source, the technology provides a sustainable, plant-based platform for developing functional peptide ingredients with tailored bioactivities.

Technical specifications

Peptide design and characterization:

• NurP28 was defined through in silico analysis of the 22-kDa alpha-zein protein sequence (UniProt entry Q00919_MAIZE)
• Three additional peptides (19ZP1, 19ZP2, 19ZP3) were characterized from the 19 kDa alpha-zein fraction
• Computational tools used include the TMHMM Server v.2.0 for transmembrane helix prediction and PROTEUS Structure Prediction Server 2.0 for structural analysis
• Peptides are derived from a plant-based, food-grade protein source, offering advantages in sustainability and consumer acceptance
• Multiple peptide variants enable exploration of diverse functional properties and application targets

Technology readiness level

The peptides have been designed and computationally characterized through in silico analysis. The current stage involves sequence definition and structural prediction. Future validation plans, including synthesis and experimental testing of bioactivity, stability, and application-specific performance, are anticipated to advance the technology toward laboratory validation and eventual scale-up. Interested partners are invited to collaborate on downstream validation and application development.